OncoLifeS

Which questions can be

answered?



Steering committee OncoLifeS (2015)

Contact information: OncoLifeS@umcg.nl








UMCG Oncology Comprehensive Cancer Center

Databiobank OncoLifeS

Organisation	 Initiated by Comprehensive Cancer Center (CCC), Dept. of Epidemiology in close cooperation with tumour boards of UMCG-CCC since end of 2014 Embedded in routine care
Collection	 Prospective inclusion after informed consent (IC) Patients with oncological diagnosis (2850 patients) Clinical, patient, treatment data, biomaterials, long term outcomes, quality of life
Unique qualities	 METC UMCG approved, ISO certified (9001:2008 Healthcare) Fulfil requirements of General Data Protection Regulation (GDPR) Privacy proof (PIA)
Data use	 Scientific board will advice steering committee and biobank manager Only processed for purposes of OncoLifeS Only coded data are released

Databiobank OncoLifeS: inclusion



Improvement of indication for diagnostics and treatment

Predictors for outcome

Outcomes:

Health-related Quality of Life

Recurrences

Survival

Predictors:

Frailty

Blood markers

Tissue markers

Imaging markers

Improvement of diagnostic and therapeutical strategies

Realised in MOC:

Int. J. Cancer: **124,** 919–923 (2009) © 2008 Wiley-Liss, Inc.

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

Nienke M. van der Velde¹, Marian J.E. Mourits¹, Henriëtte J.G. Arts¹, Jacob de Vries², Beike K. Leegte³, Grieteke Dijkhuis², Jan C. Oosterwijk³ and Geertruida H. de Bock^{4*}

Relevance UMCG

Informed consent allows researchers to analyse clinical data of their patients

- All researchers can comply to GDPR
- Structured collection of blood and tissue gives high quality material
- Patient perspective (frailty, HRQoL) gives new perspective
- Can serve as example for other researchers / biobanks